Cagri Semaglutide: What the CagriSema Combination Actually Is

Cagri semaglutide — commonly written as CagriSema — is an investigational combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist. The two compounds are studied together because they act on different appetite and blood-sugar pathways, and clinical trial data suggest the pairing may produce greater weight loss than semaglutide alone. CagriSema is not FDA-approved for any human use in the United States.

What Is the Cagri Sema Blend?

Cagri semaglutide is a fixed-dose combination product developed by Novo Nordisk under the name CagriSema. It is not a single molecule; it is two separate peptides formulated together and given as one injection. Researchers frequently refer to it as the cagri sema blend to distinguish it from either compound used alone.

Each component works through a distinct receptor system, which is the main scientific rationale for combining them. Cagrilintide mimics amylin, a hormone co-secreted with insulin that slows gastric emptying and promotes satiety. Semaglutide mimics GLP-1, a gut hormone that reduces appetite and improves glycemic control.

Feature	Cagrilintide	Semaglutide	CagriSema (combination)
Drug class	Amylin analog	GLP-1 receptor agonist	Amylin analog + GLP-1 agonist
Primary receptors	Amylin / calcitonin receptors	GLP-1 receptors	Both pathways
Injection schedule in trials	Once weekly	Once weekly	Once weekly
FDA status	Not approved	Approved as standalone products	Investigational

How Cagrilintide and Semaglutide Work Together

Amylin and GLP-1 are both satiety signals, but they reach the brain through different routes. That difference is why researchers expected an additive effect rather than a redundant one.

• Cagrilintide slows stomach emptying and signals fullness through hindbrain amylin receptors.
• Semaglutide reduces appetite through hypothalamic GLP-1 receptors and improves insulin secretion in a glucose-dependent way.
• Together, the two compounds appear to hit appetite regulation from two angles at once, which may explain the larger average weight reductions seen in trials.

Many people exploring this category also research cagrilintide and semaglutide separately to understand what each component contributes on its own.

What the REDEFINE Trials Reported

The CagriSema program includes the REDEFINE phase 3 trials, which enrolled adults with overweight, obesity, and type 2 diabetes. Results have been presented at major medical conferences and published in peer-reviewed journals.

Trial	Population	Reported average weight change
REDEFINE 1	Adults with obesity or overweight without diabetes	Roughly 20% with CagriSema versus about 15% with semaglutide 2.4 mg over 68 weeks (intention-to-treat analysis)
REDEFINE 2	Adults with type 2 diabetes and overweight or obesity	Approximately 15% with CagriSema over 68 weeks

These are group averages from controlled research settings, not predictions of what any individual would experience. The trials also reported reductions in HbA1c and improvements in several cardiovascular risk markers.

Cagrilintide Semaglutide Dosage in Research Settings

In the phase 3 program, participants received 2.4 mg of cagrilintide plus 2.4 mg of semaglutide, injected once weekly. Doses were escalated gradually over about 16 weeks to limit gastrointestinal discomfort.

This matters because cagrilintide semaglutide dosage varies widely in gray-market listings, and many vendors sell vials with no verified concentration or purity data. There is no validated human dosing schedule for compounded or research-grade versions of this combination.

Side Effects and Safety Considerations

The adverse event profile of CagriSema looks similar to that of GLP-1 and amylin therapies individually. Most reported effects are gastrointestinal and tend to ease as the body adjusts.

• Nausea, vomiting, and diarrhea
• Constipation or abdominal discomfort
• Injection-site reactions
• Reduced appetite and, in some cases, fatigue

Less common but more serious concerns reported across this drug class include gallbladder disease, pancreatitis, and hypoglycemia when combined with insulin or sulfonylureas. People investigating similar research peptides often compare reta cagri blend side effects against what has been documented for CagriSema, though the two combinations have different safety datasets.

Semaglutide carries a boxed warning for thyroid C-cell tumors based on animal studies and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Anyone considering any GLP-1 or amylin-based product should talk with a licensed healthcare professional first.

Legal Status and What Buyers Should Know

Cagrilintide is not approved by the FDA for any indication, and no FDA-approved product combines cagrilintide with semaglutide. Semaglutide itself is approved under brand names such as Ozempic, Wegovy, and Rybelsus, but those approvals cover semaglutide alone.

Products sold online as "cagri semaglutide" or "research-grade CagriSema" are typically labeled for laboratory research only and are not intended for human consumption. They are not manufactured under the same quality standards as approved pharmaceuticals, and their sterility, purity, and actual peptide content are usually unverified.

Related Combinations People Research

Curiosity about CagriSema often leads to adjacent research blends. Some people compare cagri reta blend benefits when reading about amylin analogs paired with triple agonists, while others look into aod 9604 and semaglutide or semaglutide l carnitine formulations sold through similar channels. None of these combinations are FDA-approved, and none should be treated as interchangeable with a prescribed medication.

The Bottom Line

Cagri semaglutide is a promising investigational combination that may offer greater average weight loss than semaglutide alone in clinical trials. It remains unapproved in the United States, and unregulated versions sold online carry unclear purity, dosing, and safety risks. Decisions about any GLP-1 or amylin-based therapy belong with a qualified medical professional, not a research chemical vendor.

COMMON QUESTIONS

Frequently Asked Questions

Is cagri semaglutide FDA-approved?

No. CagriSema, the combination of cagrilintide and semaglutide, is still investigational in the United States and has not received FDA approval for any human use. Semaglutide is approved as a standalone drug, but cagrilintide is not approved at all.

What is the difference between cagrilintide and semaglutide?

Cagrilintide is a long-acting amylin analog that slows gastric emptying and signals fullness through amylin receptors, while semaglutide is a GLP-1 receptor agonist that reduces appetite and improves blood sugar control. They target different receptor systems, which is why researchers combined them.

Is cagri semaglutide the same as Ozempic or Wegovy?

No. Ozempic and Wegovy contain semaglutide only. CagriSema adds cagrilintide, a second peptide with a different mechanism, and the combination is not approved for sale as a prescription medication in the US.